Nortriptyline
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Nortriptyline: From Anxiety Disorder to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Nortriptyline is a tricyclic antidepressant, originally associated with anxiety disorder, neurotic disorder and dysthymic disorder. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), with no registered clinical trials but 15 publications (including one controlled study in children and adolescents and a Cochrane-type review of tricyclics for ADHD) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder, neurotic disorder, dysthymic disorder (from the knowledge graph; no approved indication text is available in Singapore licence records) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L2 (see note below) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Note on evidence level: No completed Phase 2/3 trials are registered. The L2 rating rests on a published randomized controlled study in children and adolescents with ADHD (PMID 11052409). By the strict trial-based rules this would be closer to L3, so the rating should be read as conservative-to-moderate.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, nortriptyline is a tricyclic antidepressant that mainly inhibits norepinephrine reuptake, with weaker effects on serotonin. Noradrenergic enhancement in prefrontal circuits is also the mechanism of non-stimulant ADHD drugs such as atomoxetine, which gives a plausible basis for efficacy.
The original indications (anxiety, neurotic and dysthymic disorders) and ADHD are all neuropsychiatric conditions that respond to modulation of monoamine signalling. A PET study (PMID 24345533) showed nortriptyline occupies the norepinephrine transporter in patients, supporting target engagement in the relevant system. Reviews describe the more noradrenergic secondary-amine tricyclics (desipramine and nortriptyline) as established alternative treatments for ADHD, although their narrow therapeutic index and cardiovascular toxicity have limited use.
Clinical Trial Evidence
Currently no clinical trials registered for ADHD. (Trials listed for the lower-ranked prediction "major affective disorder" concern depression, which is an established use of nortriptyline rather than a new indication, and are not counted here.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11052409 | 2000 | RCT | J Child Adolesc Psychopharmacol | Controlled study of nortriptyline efficacy and tolerability in children and adolescents with ADHD |
| 25238582 | 2014 | Systematic Review | Cochrane Database Syst Rev | Tricyclic antidepressants as second-line treatment for ADHD in children and adolescents |
| 15064003 | 2004 | Review | Psychiatr Clin North Am | Nonstimulant treatments for adult ADHD; nortriptyline and desipramine are the more noradrenergic tricyclics but have cardiovascular limits |
| 12270803 | 2002 | Review | Adolesc Med | Medication review for adolescent ADHD, listing nortriptyline among effective tricyclics |
| 8428873 | 1993 | Clinical study | J Am Acad Child Adolesc Psychiatry | Nortriptyline in children with ADHD and tic disorder or Tourette's syndrome |
| 8444763 | 1993 | Chart review | J Am Acad Child Adolesc Psychiatry | Chart review of 58 cases of nortriptyline treatment for ADHD |
| 22700161 | 2012 | RCT | Pediatr Nephrol | Randomized double-blind trial of nortriptyline for enuresis in children with ADHD |
| 8444754 | 1993 | Retrospective study | J Am Acad Child Adolesc Psychiatry | Serum levels and ECG effects of nortriptyline in children and adolescents |
| 4075308 | 1985 | Clinical study | Clin Neuropharmacol | Early report of nortriptyline in attention deficit disorder |
| 22303520 | 2012 | Guideline | Ann Clin Psychiatry | CANMAT recommendations for mood disorders with comorbid ADHD |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09253P | APO-NORTRIPTYLINE CAPSULE 25 mg | Capsule | Not available |
| SIN09255P | APO-NORTRIPTYLINE CAPSULE 10 mg | Capsule | Not available |
Both products are single-ingredient oral capsules made by Apotex Inc and are currently valid.
Safety Considerations
- Contraindications (from the knowledge graph, not label text): long QT syndrome (including familial), torsades de pointes, sudden cardiac arrest, heart conduction disease, myocardial infarction and coronary thrombosis, stroke and other cerebrovascular disorders, cerebral infarction, epilepsy, manic bipolar affective disorder, open-angle glaucoma and glaucoma, benign prostatic hyperplasia, substance abuse/dependence, liver failure, kidney failure and uremia, hyperthyroidism (Graves disease, thyrotoxicosis), and hemoglobinopathy.
- Drug Interactions: 100 interactions were identified. Major-level examples include epinephrine, bupropion, lorcaserin, potassium citrate and dolasetron. Moderate-level examples include famotidine, cimetidine, clarithromycin, morphine, loperamide, and several anticholinergics (atropine, hyoscyamine, glycopyrronium, dicyclomine).
- ADHD-specific considerations (from the literature): cardiac conduction effects and a narrow therapeutic index, anticholinergic effects, and overdose toxicity. ECG monitoring is advisable, particularly in children and adolescents. Tricyclics can occasionally worsen tics.
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Nortriptyline has a plausible noradrenergic mechanism for ADHD, a published controlled study in children and adolescents, a Cochrane-type review and several supporting clinical reports. However, there are no registered trials, the key studies are small and dated, and the cardiac and anticholinergic safety profile is a significant limitation compared with current first-line options.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore Health Sciences Authority (HSA), which are currently missing and are required for safety screening
- Detailed mechanism of action data
- A cardiac safety plan, including baseline and follow-up ECG, especially for patients with the conduction or QT-related conditions listed above
- Review of the interaction list against typical ADHD co-medications
- Ideally, a modern controlled trial in the target population, positioned against current standard ADHD treatments
Other Predicted Indications (Brief)
| Predicted Indication | Score | Evidence Level | Suggested Stance | |------|------|------|------| | ADHD, inattentive type | 99.33% | L4 | Research question; indirect support from parent ADHD evidence only | | Faciodigitogenital syndrome | 98.82% | L5 | Hold; no mechanistic link | | Chondromyxoid fibroma | 98.82% | L5 | Hold; no mechanistic link | | Specific developmental disorder | 98.78% | L5 | Hold; retrieved literature concerns depression, not this condition | | Benign paroxysmal torticollis of infancy | 98.25% | L5 | Hold; no evidence, and infant safety concerns | | Agoraphobia | 97.61% | L3 | Research question; a small 1988 study in panic disorder with agoraphobia (PMID 3379145), with SSRIs now preferred | | Trichotillomania | 96.77% | L5 | Hold; prediction only | | Tourette syndrome | 96.05% | L3 | Research question; evidence is limited to ADHD with comorbid tics | | Major affective disorder | 95.51% | L3 | Research question; this is essentially an established antidepressant use rather than true repurposing, and trial-level attribution to nortriptyline is uncertain |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.